Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 2025Clinical Cancer Research

Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance

View Full Paper
Ask AI
Bookmark
Share

Authors

RFRoss FirestoneASAnish K. SimhalDMDevin McAvoy

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows immune-MRD status predicts progression free survival in multiple myeloma, suggesting new management strategies for patients.

Key Points

  • Patients with MRDres experienced worse progression free survival compared to sustained MRD-negative patients, highlighting the significance of MRD status.
  • At the 1- and 2-year marks, the PFS difference was statistically significant (P=0.036, P=0.0014).
  • Single-arm phase 2 study assessed five years of lenalidomide maintenance alongside immune profiling using spectral cytometry.
  • Immune-MRD status signifies a pivotal role in segregating patients with early progression and stable remissions despite MRD presence.

Cite This Study

Firestone et al. (2025) studied this question.

synapsesocial.com/papers/68af7b2a7567bf4f94ff322chttps://doi.org/10.1158/1078-0432.ccr-25-0572
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world study on discontinuation strategies after MRD negativity in multiple myeloma patients2025
  2. 2Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  3. 3Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.2025
  4. 4Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  5. 5The role of maintenance therapy and its cessation in patients with multiple myeloma2025